Parkinson's Disease Research

The Research Pipeline: From Laboratory to Patient

Parkinson's research spans a broad pipeline. At one end, basic scientists are uncovering the molecular mechanisms that drive neurodegeneration — the roles of alpha-synuclein aggregation, lysosomal dysfunction, neuroinflammation, and mitochondrial failure. At the other end, pharmaceutical companies are conducting large Phase 3 trials needed for regulatory approval. In between, translational researchers are testing gene therapies, stem cell transplants, and repurposed drugs in early-phase clinical trials, while biomarker scientists develop tools to detect the disease earlier and measure whether experimental treatments truly slow progression.

It is important to approach these advances with informed realism. The path from laboratory discovery to approved therapy typically takes 10 to 15 years, and most clinical trials do not meet their primary endpoints. Yet the breadth and sophistication of current research — targeting multiple disease mechanisms simultaneously, using precision-medicine approaches, and leveraging new biomarkers for earlier intervention — are unprecedented. The articles below cover the major areas of active investigation.